Acurx Pharmaceuticals, Inc.
ACXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.12 | 0.03 | 0.24 |
| FCF Yield | -80,280.40% | -13.73% | -26.25% | -16.23% |
| EV / EBITDA | 0.00 | -2.72 | -1.48 | -3.65 |
| Quality | ||||
| ROIC | 0.00% | -63.64% | -92.98% | -452.23% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.74 | 0.95 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -335,073.42% | 18.57% | 8.84% | -2.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 2.70 | 2.16 | 1.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |